Diffusion Pharmaceuticals Inc (DFFN)

[Fluffy100]

Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen 'Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients'
4:00 pm ET December 10, 2019 (Benzinga) Print
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces the presentation of data signaling increased survival in inoperable glioblastoma multiforme (GBM) patients enrolled in the 19-patient lead-in portion of its open-label, dose-escalation Phase 3 study with Trans Sodium Crocetinate (TSC) plus standard of care (SOC). Chief Scientific Officer John Gainer, Ph.D. presented these findings today at the inaugural Glioblastoma Drug Development Summit in Boston, sponsored by Hanson Wade.

Dr. Gainer’s presentation included earlier research demonstrating that TSC safely reduces tumor hypoxia by a novel mechanism of action, making the tumor up to 3 times more susceptible to radiation and chemotherapy. In Phase 2 testing of TSC in newly diagnosed inoperable GBM patients, a nearly 4-fold increase in 2-year survival was seen compared with historical controls.